Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Scaling Tableau
